Zai Lab

#Breaking at #AAI2026: We're sharing positive preclinical study results from our investigational bispecific antibody in atopic dermatitis and other disease models. Learn more: tinyurl.com/4wbxvmr2

At #AACR26, we will present data demonstrating the progress of our #oncology pipeline, including important new data for our investigational treatment for people with small-cell lung cancer. Learn more: tinyurl.com/4cn6zmes

#NEWS: We announced a clinical collaboration with @Boehringer to pioneer a potential dual DLL3-targeting investigational combination for small-cell lung cancer and other neuroendocrine carcinomas. Learn more: tinyurl.com/2vyyhy5r #SLC #Innovation #Oncology

Zai Lab joins the World Health Organization in celebrating this year’s World Health Day theme: “Together for health. #StandWithScience.” Learn more about this year’s World Health Day campaign: tinyurl.com/5n9xt2pd #WorldHealthDay #Innovation #Biotech #Innovation

#NEWS: Zai Lab announces global clinical trial collaboration and supply agreement with @Amgen Learn more: lnkd.in/gBVS8nJC

#NEWS: Zai Lab will present new data on three internally developed oncology candidates at #AACR26, including zoci (DLL3 ADC), ZL‑6201 (LRRC15 ADC), and ZL‑1222 (PD‑1/IL‑12). Learn more: tinyurl.com/398k89ek #ADC #Oncology #Immunotherapy

#IWD26: This International Women’s Day, we’re celebrating some of our colleagues whose leadership fuels our mission to bring innovative treatments to patients in need. Embracing this year’s theme, #GivetoGain, we recognize how collaboration & innovation strengthen our culture.

#NEWS: Zai Lab President & COO Josh Smiley joins Meredith Heyman from @IBDinvestors to discuss China’s rapidly advancing biotech ecosystem, the power of cross-border collaboration, and how these dynamics are shaping global innovation. youtu.be/dwMwCSH3568 #biotech #innovation

#NEWS: Zai Lab announces fourth quarter and full-year 2025 financial results along with recent product highlights and corporate updates. Learn more about our pipeline progress and healthcare innovation: tinyurl.com/5753jbdd #earnings #financialresults #oncology #ADC

Celebrating five years of partnership with @argenxglobal. Together, we’ve accelerated development, expanded patient access, and supported thousands across China—including those living with gMG and CIDP. Grateful for our teams driving impact and innovation forward. #LifeSciences

We’re #Hiring: Senior Medical Director, Oncology — Cambridge, MA or South SF, CA. If you’re passionate about advancing innovative oncology therapies and excel at scientific leadership, strategic execution, and cross team collaboration — apply now: bit.ly/3MhDC6A

#NEWS: Zai Lab President & COO Josh Smiley speaks with @IBDinvestors about China’s evolving role in the global biotech landscape and the collaboration opportunities emerging in the market. Read more: bit.ly/4kqp0hP #biotech #pharma

China’s as a rising source of global biotech innovation: on The Top Line by @FierceBiotech, Zai Lab President & COO Josh Smiley shares insights on regulatory shifts, R&D growth, and Zai Lab’s global development model for accelerating programs like Zoci. bit.ly/456HUUq

#NEWS: Zai Lab will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco today @ 3PM PT / 6PM ET. Learn more about our 2026 strategic priorities and global pipeline progress: bit.ly/3NgL81C #JPM26 #Innovation #ADC #oncology

@LMatuson71920 Thanks for your note, we will send you a direct message.

@ZaiLab_Global Please can you let me know when the roll out is going to happen . My son Anthony chang needs cobenfy I am prepared to travel . My contact details are e mail leegmat@hotmail.com. Cell +27 741043108

#NEWS: Zai's President & COO featured on Denatured, a @biospace podcast. Hear Josh’s insights on this pivotal moment in biotech innovation and discover what’s shaping biotech’s next chapter—market trends, global partnerships, & the future of life sciences: bit.ly/4s3Kapn

#NEWS: Zai Lab dosed the first participant in our Global Phase 1/1b study of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis. Discover the potential of ZL-1503: bit.ly/4rFqqs5

Zai Lab's President and COO Josh Smiley spoke at @FinancialTimes Global Pharma and Biotech Summit in London today on a panel discussing China's transformation into a biopharma innovation powerhouse. #FTPharma #Innovation #Biotech #BioPharma

#NEWS: Zai Lab announces third quarter 2025 financial results along with recent product highlights and corporate updates. Learn more about our pipeline progress and healthcare innovation: bit.ly/47uR3rG #earnings #financialresults #oncology #ADC #healthcare #innovation

#NEWS: Zai Lab announces updated data from the global Ph1 clinical trial of zocilurtatug pelitecan (zoci)—formerly ZL-1310— today at the AACR-NCI-EORTC International Conference. Learn more about the initiation of our global Ph3 Registrational Study: bit.ly/3WUKbgS #ADC